Elucidation of the Mechanisms through Which the Reactive Metabolite Diclofenac Acyl Glucuronide Can Mediate Toxicity

Renato J. Scialis and José E. Manautou
Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut

Received November 15, 2015; accepted February 10, 2016

ABSTRACT
We have previously reported that mice lacking the efflux transporter Mrp3 had significant intestinal injury after toxic diclofenac (DCF) challenge, and proposed that diclofenac acyl glucuronide (DCF-AG), as a substrate of Mrp3, played a part in mediating injury. Since both humans and mice express the uptake transporter OATP2B1 in the intestines, OATP2B1 was characterized for DCF-AG uptake. In vitro assays using human embryonic kidney (HEK)-OATP2B1 cells demonstrated that DCF-AG was a substrate with a maximal velocity ($V_{max}$) and $K_m$ of $17.6 \pm 1.5 \text{ pmol/min per milligram}$ and $14.3 \pm 0.1 \text{ M}$, respectively. Another key finding from our in vitro assays was that DCF-AG was more cytotoxic compared with DCF, and toxicity occurred within 1–3 hours of exposure. We also report that 1 mM DCF-AG caused a 6-fold increase in reactive oxygen species (ROS) by 3 hours. Investigation of oxidative stress through inhibition of superoxide dismutase (SOD) revealed that DCF-AG had 100% inhibition of SOD at the highest tested dose of 1 mM. The SOD and ROS results strongly suggest DCF-AG induced oxidative stress in vitro. Lastly, DCF-AG was screened for pharmacologic activity against COX-1 and COX-2 and was found to have $IC_{50}$ values of $0.620 \pm 0.105$ and $2.91 \pm 0.36 \text{ M}$, respectively, which represents a novel finding. Since cyclooxygenase (COX) inhibition can lead to intestinal ulceration, it is plausible that DCF-AG can also contribute to enteropathy via COX inhibition. Taken in context, the work presented herein demonstrated the multifactorial pathways by which DCF-AG can act as a direct contributor to toxicity following DCF administration.

Introduction
Prior work on diclofenac (DCF) and its glucuronide metabolite, diclofenac acyl glucuronide (DCF-AG), focused on their disposition and the contribution of efflux transporters in modulating toxic outcomes. Mutant Wistar rats lacking the efflux transporter Mrp2 ($Abcg2$) exhibited resistance to intestinal injury after DCF administration compared with nonmutant rats (Seitz and Boelsterli, 1998). It was also determined that DCF-AG administration led to increased gastrointestinal (GI) ulceration compared with DCF administration. Since DCF is glucuronidated to DCF-AG, a known Mrp2 substrate (Seitz and Boelsterli, 1998), the intestinal toxicity in nonmutant rats was probably attributable to DCF-AG. A recent study reported that a single 50-mg oral DCF dose to humans resulted in a DCF-AG plasma exposure that was comparable to DCF exposure, indicating DCF-AG formation constitutes a significant metabolic pathway (Zhang et al., 2015). Our work with efflux transporters demonstrated Bcrp ($Abcg2$) and Mrp3 ($Abcc3$) have functional roles with respect to DCF and DCF-AG disposition (submission pending). Toxicodynamic studies conducted in Mrp3 knockout (KO) mice showed conclusively that KO mice developed increased intestinal damage compared with wild-type (WT) (Seialis et al., 2015). Despite the susceptibility differences between genotypes, the mechanisms for the increased injury remain unclear.

DCF administration leads to the covalent adduct formation along the intestinal epithelia, with addition occurring at the brush border and within enterocytes (Ware et al., 1998; Atchison et al., 2000). Adduction on the extracellular surface of plasma membrane was probably followed by internalization of the adducted protein (Boelsterli, 2003). Another pathway may involve DCF-AG uptake by intestinal transporters followed by intracellular adduction. Indeed, the GI tract expresses a number of transporters that have been quantified by liquid chromatography–tandem mass spectrometry (LC–MS/MS; Groer et al., 2013). One of the major uptake transporters is OATP2B1 ($SLCO2B1$), a known carrier for conjugated substances (Gao et al., 2012).

There is a distinct possibility that DCF-AG uptake by organic anion–transporting polypeptide (OATP) was contributory
to the enteropathy observed in our animal models. Evidence for transporter uptake causing injury has gained recent attention. Stably transected human embryonic kidney (HEK)-OATP cells were used to explore toxicity resulting from transporter-mediated uptake of statins wherein active uptake by OATP1B1 (SCLO1B1) caused a left-shift in cytotoxicity potency compared with the toxicity observed in HEK-WT cells (Zhang et al., 2013). Since OATP2B1 intestinal expression and activity have been demonstrated (Sai et al., 2006), understanding the relationship between intestinal uptake and toxicity should be pursued.

Intestinal enteropathy is probably not mediated through covalent adduct formation by reactive DCF metabolites. The argument against covalent adduction as an injury mechanism was supported by our observation that covalent adducts were observed in the liver without apparent toxicity or morphologic changes following DCF administration (Scialis et al., 2015). A possible causal factor for enteropathy is oxidative stress through inhibition of superoxide dismutase (SOD), which is a critical cellular defense mechanism for coping with reactive oxygen species (ROS) (Fridovich, 1978). Precedent of SOD inhibition by xenobiotic metabolites comes from a study by Chio et al. (1999), in which suprofen acyl glucuronide inhibited SOD. In addition to SOD perturbation, DCF-AG may induce oxidative stress by generation of ROS just as DCF has been shown to incite (Lim et al., 2006).

Gastrointestinal injury after DCF administration occurs through inhibition of cyclooxygenan (COX) enzymes that metabolize arachidonic acid into physiologically important cytotoxic or important metabolites such as prostaglandin E2 (PGE2) (Kotani et al., 2006). DCF, a nonselective inhibitor of COX-1 and COX-2, promotes GI injury though decreased PGE2 signaling. Inhibition of both COX isoforms is necessary for injury to develop, and selective COX inhibitors fail to show significant GI damage (Tanaka et al., 2001). DCF’s ability to provoke injury makes clear that promiscuity for general COX inhibition, rather than potency against a single COX isoform, is pivotal. Since hydroxylated DCF metabolites have shown pharmacological activity against COX, the inhibition of COX by DCF-AG should be explored. Though conjugated metabolites are normally thought to be pharmacologically inactive, glucuronide metabolites with pharmacologic potency equivalent to their parent compound have been reported (Osborne et al., 1992; Schutz et al., 1999). In light of this, DCF-AG may possess enough COX inhibition pharmacology to promote injury.

Our hypothesis is that DCF-AG, as a major metabolite observed in animal models and human subjects, can directly mediate intestinal toxicity through pathways that occur in parallel to or independent from DCF. Thus the goal of the current work was to identify the various mechanisms that DCF-AG can promote injury. This was accomplished through analysis of OATP2B1-mediated uptake of DCF-AG, and by conducting in vitro assays to quantify the extent of cytotoxicity as a result of ROS generation or inhibition of COX and SOD enzymes.

**Materials and Methods**

**Chemicals and Reagents.** DCF, DCFDA, Dulbecco’s modified Eagle’s medium (DMEM), formic acid, hydrogen peroxide, HEPES, indomethacin (used as the internal standard), MOPS, and SC-560 were purchased from Sigma-Aldrich (MilliporeSigma, St. Louis, MO).

DCF-AG was purchased from Toronto Research Chemicals Incorporated (Toronto, Canada). Arachidonic acid (AA), COX-1, COX-2, Dup-697, and SOD were purchased from Cayman Chemical (Ann Arbor, MI). Calcein-AM was purchased from Thermo Fisher Scientific, Inc. (Waltham, MA). Ethidium homodimer-1 was purchased from Biotium Inc. (Hayward, CA). Stably-transfected HEK-OATP2B1 cells were created at Pfizer Inc. (Sandwich, UK) and were previously described (Kalpatkar et al., 2013). All LC–MS/MS solvents were of high analytical grade and were purchased from Burdick and Jackson (Muskegon, MI).

**In Vitro Transport.** HEK-WT and HEK-OATP2B1 cells were seeded at 60,000 and 90,000 cells/well, respectively, in 96-well poly-d-lysine coated microplates. Cells were grown in DMEM containing 10% heat-inactivated fetal bovine serum and 5 mM sodium pyruvate. Plates were kept in an incubator set to 95% relative humidity, 5% CO2, and 37°C. Upon reaching confluency 48 hours after seeding, the growth media was discarded, and cells were washed three times with 100 µl of uptake buffer at 37°C. Two types of buffer were used for the studies: 1) Hanks’ balanced salt solution (HBSS) supplemented with 20 mM HEPES and titrated to pH 7.4, and 2) HBSS fortified with 20 mM MOPS and titrated to pH 6.0. The last wash was left of the cells for 15 minutes to equilibrate the cells before dosing commenced. After the equilibration period had passed, the last wash was removed and cells were dosed with 50 µl of uptake buffer containing increasing DCF-AG concentrations. Plates were quickly placed on a shaker set to 150 rpm and 37°C and incubated for 0.1, 0.5, 1, and 2 minutes. Termination of uptake was performed by quickly removing the uptake buffer, and the cells were washed four times with 200 µl of ice-cold uptake buffer. Intracellular DCF-AG was extracted by adding the internal standard (IS) in 100 µl of ice-cold methanol and shaking the cell plates for 15 minutes at 4°C. Cellular extracts were transferred into a clean 1-ml deep-well microplate and mixed with 100 µl of solvent A. Sample plates were vigorously vortex-mixed and injected onto the LC–MS/MS. A DCF-AG standard curve was prepared using naïve cells and extracted using the same process described for samples. The injection volume for all sample types was 10 µl. Total DCF-AG uptake was quantified using the standard curve, and the data were reported as picomoles. Cell counts and cell size were measured using a Scepter device (EMD Millipore, Billerica, MA), and total protein was determined using a Pierce BCA kit following the manufacturer’s recommendations (Thermo Fisher Scientific Incorporated, Waltham, MA). Concentrations were then normalized to picomoles per microliter of total cell volume in each well.

**Kinetic Modeling.** The DCF-AG uptake data were subsequently analyzed using a two-compartment model previously described for OATP-mediated uptake (Poirier et al., 2008, 2009). Essentially, the model is governed by three processes: 1) \( P_{diff,in} \) defined as passive diffusion from the media into the cell; 2) \( K_{active} \) which is active transport from the media into the cell; and 3) \( P_{diff,out} \) representing passive diffusion from the cell into the media. A schematic of the model is shown in Fig. 1. Each process is described using the following equations:

\[
P_{diff} = P_{diff} \times C_{media}
\]

\[
K_{active} = \frac{V_{max} \times C_{media}}{K_m + C_{media}}
\]

\[
P_{diff,out} = P_{diff} \times C_{cell}
\]

where \( P_{diff} \) was a passive diffusion constant (µl/min), \( C_{media} \) was the DCF-AG concentration of the media, \( V_{max} \) was the maximal transport velocity (pmol/min), \( C_{cell} \) is the intracellular DCF-AG concentration (µM). The \( P_{diff} \) and \( V_{max} \) parameters noted above were normalized by the total cellular protein per well to yield units of µl/min per milligram and pmol/min per milligram, respectively. The amount of DCF-AG in each compartment was defined by:
The order Runge-Kutta integration algorithm was implemented using Berkeley Madonna software v8.3.18 (Macey et al., 2000). A fourth

The concentrations from the uptake studies were imported into Berkeley Madonna software v8.3.18 to derive kinetic parameters such as $K_m$, $P_{diff}$, and $V_{max}$. $P_{diff}$ reflects passive diffusion while $K_m$ and $V_{max}$ are used to characterize active uptake that adheres to Michaelis-Menten kinetics. Kinetic parameterization was performed for uptake at pH 6.0 and 7.4 to reflect the physiologic conditions of the intestine and liver, respectively.

$$\frac{dA_{cell}}{dt} = K_{active} + P_{diff, in} - P_{diff, out}$$

where $A_{media}$ and $A_{cell}$ were the DCF-AG amounts (pmol), $V_{media}$ was the volume of the dosing buffer (50 μL), and $V_{cell}$ was the total cellular volume per well (μL) that was determined during the cell counting procedure using total cell counts and cell diameter. Utilizing the previously described relationships, the temporal uptake of DCF-AG into cells was derived from the following differential equation:

$$A_{media} = C_{media} \times V_{media}$$

$$A_{cell} = C_{media} \times V_{cell}$$

The SOD inhibition protocol. Briefly, SOD incubations consisted of 198 μl of radical detector, 10 μl of copper/zinc SOD, and 2.3 μl of vehicle or increasing concentration of inhibitor. Reactions commenced upon the addition of 20 μl of xanthine oxidase, and the mixtures were shaken at 60 rpm in the dark for 30 minutes at room temperature. Samples were then read on a BioTek UV/Vis microplate spectrophotometer (BioTek Instruments Incorporated, Winooski, VT) at a wavelength of 450 nm. The SOD activity in all samples was compared against a SOD standard curve. Absorption responses were background subtracted, and the percentage SOD inhibition was determined by normalizing the inhibitor response to vehicle controls.

**COX Inhibition Assay.** The COX assay was performed using a Cayman Chemical COX kit with minor modifications to the recommended protocol. Briefly, COX incubations consisted of 194 μl of reaction buffer, 2 μl of heme, 2 μl of COX (1 or 2) enzyme, 2 μl of AA, and 4 μl of vehicle or increasing concentration of inhibitor. Reactions were conducted for 2 minutes in duplicate at 37°C and were quenched by the addition of 10 μl of 1 M HCl. A 200-μl aliquot of the quenched reaction was transferred into a 1-mL deep-well microplate and diluted with 200 μl of ice-cold methanol. From the diluted mixture, a 100-μl aliquot was mixed with 100 μl of IS in ice-cold methanol, vigorously vortex-mixed, and injected onto the LC–MS/MS. Methodology for detecting analytes of interest were modified from Shinde et al. (2012). The injection volume for all sample types was 10 μl. Rather than merely follow AA depletion, COX inhibition was determined by monitoring the appearance of PGE$_2$ (PGE$_2$/IS peak area ratio) in all samples and normalizing the inhibitor response to vehicle controls.

**LC–MS/MS Method.** Chromatographic separation of analytes was performed on a Kinetex XB-C18 30 2.6 μm × 2 mm column (Phenomenex Incorporated, Torrance, CA). The system front end consisted of a HTC PAL Autosampler (LEAP Technologies, Carrboro, NC), a CMB-20A system controller, two LC20Advp pumps, and a DGU-14A degasser (Shimadzu Scientific Instruments, Columbia, MD). Analytes of interest were eluted using one of two gradient profiles: method 1 (for DCF-AG) began with 10% solvent B for the first 0.5 minutes, which was then increased to 90% solvent B at 1.25 minutes using a linear gradient and held at this mixture for 0.25 minutes before reverting back to initial solvent conditions for 0.5 minutes to re-equilibrate the column, and method 2 (for PGE$_2$) began with 10% solvent B for the first 0.5 minutes, which was then increased to 95% solvent B at 2.00 minutes using a linear gradient and held at this mixture for 0.5 minutes before reverting back to initial solvent conditions for 0.5 minutes to re-equilibrate the column. The flow rate for both methods was 0.3 ml/min, and the column effluent was directed to waste for the initial 0.5 minutes before being switched to the mass spectrometer. Analytes were detected using an AB Sciex API 4000 LC–MS/MS triple quad mass-spectrometer with a TurbolonSpray probe and Analyst version 1.5.2 software (AB Sciex, Framingham, MA) that was operated in multiple reaction monitoring mode. Ion spray voltage was −4250 V, and the source temperature was set to 400°C.

The mass transitions in negative ion mode for monitoring AA, DCF-AG, PGE$_2$, and indomethacin were mass-to-charge ratio (m/z) 303.3→259.0, 470.1→192.9, 351.5→271.0, and 356.0→311.8, respectively. The retention times of AA, DCF-AG, PGE$_2$, and indomethacin
Fig. 2. Concentration-versus-time profiles of DCF-AG uptake by OATP2B1. HEK-WT and HEK-OATP2B1 cells were seeded for 48 hours and incubated with increasing concentrations of DCF-AG at multiple time points in buffer titrated to either pH 6.0 or 7.4 at 37°C. Intracellular concentrations were determined by LC-MS/MS, and the concentrations were modeled in Berkeley Madonna. (A) and (B) show the uptake of DCF-AG by HEK-OATP2B1 cells at pH 6.0 and 7.4, respectively. Fitted lines from a two-compartment model represent the best fit. Data are the individual replicates from a typical study.

were 2.46, 1.32, 1.55, and 1.47 (1.85 for method 2) minutes, respectively. Concentrations of analytes in the samples were determined by comparing the peak area ratios (analyte/IS) to those in the standard curve using a linear regression model. The criterion of acceptance for standards was defined to be ±20% of nominal concentration.

Statistical Analysis. Data are expressed as mean ± standard error of the mean. P values ≤0.05 were considered statistically significant. Statistical analysis of data were performed using R version 3.2.1 (R Core Team, 2015). Two groups were compared by Student’s t test, and multiple groups were compared by an analysis of variance followed by Tukey’s post hoc test. GraphPad Prism version 6.0 (GraphPad Software Incorporated, La Jolla, CA) was used to calculate the IC_{50} for COX inhibition assays.

Results

In Vitro Transport. The uptake of DCF-AG by a major intestinal transporter was measured using stably transfected HEK-OATP2B1 cells. DCF-AG kinetic uptake by OATP2B1 was measured at pH 6.0 and 7.4 to reflect the physiologic conditions that OATP2B1 is exposed to in the intestine and liver, respectively (Fallingborg, 1999). DCF-AG was incubated at six concentrations ranging from 1 to 300 μM with time points taken at 0.1, 0.5, 1, and 2 minutes. The uptake of DCF-AG was both time- and concentration-dependent (Fig. 2). Concentration-versus-time data were then analyzed using a two-compartment model as shown in Fig. 1. The model was used to estimate transporter kinetic parameters that are summarized in Table 1. The kinetic parameters of V_{max}, K_{m}, and P_{dif} at pH 6.0 were 27.8 ± 4.1 pmol/min per milligram, 15.2 ± 0.8 μM, and 0.0522 ± 0.0120 pmol/min per milligram, respectively. It was determined that at pH 7.4, DCF-AG has V_{max}, K_{m}, and P_{dif} values of 17.6 ± 1.5 pmol/min per milligram, 14.3 ± 0.1 μM, and 0.0245 ± 0.0030 pmol/min per milligram, respectively. The higher V_{max} and P_{dif} values at pH 6.0 were found to be statistically significant compared with the parameter estimates at pH 7.4.

Cytotoxicity Assay. Having established a role for OATP2B1-mediated uptake of DCF-AG, HEK-OATP2B1 cells were incubated with DCF or DCF-AG and monitored over time. Cell viability was assessed using two fluorescent dyes that offer different modalities and are complementary to each other. Cell viability measured by CAM, which detects intact cells through esterase activity, indicated that as early as 3 hours, cell death by DCF was apparent at the 1 mM dose and by 12 hours 29% of all cells were dead (Fig. 3A). The cell viability was confirmed by EthD-1, which detects cell death by binding to DNA once the nuclear envelope becomes compromised, and EthD-1 response increased by a maximum of 1.3-fold for the 12-hour 1 mM incubation (Fig. 3C). Compared with DCF, DCF-AG induced greater cell death. After 3 hours, approximately 61% of cells were dead at the 1 mM dose, and the number of dead cells increased to 85% by 12 hours for the 1 mM condition (Fig. 3B). EthD-1 in DCF-AG incubations corroborated the CAM results. The EthD-1 response for a 12-hour incubation with 1 mM DCF increased over 2-fold compared with vehicle control (Fig. 3D).

ROS Assay. Taking into account that DCF had been shown to promote generation of reactive oxygen species, we investigated if DCF-AG had a similar potential. As for the cytotoxicity assay, HEK-OATP2B1 were exposed to DCF or DCF-AG and observed for ROS generation. Since cytotoxicity was evident by 3 hours, the ROS assay was conducted from 1 to 3 hours to determine if ROS preceded cell death. ROS production was measured with the fluorescent probe DCFDA. Hydrogen peroxide, a known ROS producer, was used as positive control and exhibited an increase in DCFDA signal in a dose-dependent manner (Fig. 4A). All hydrogen peroxide incubations achieved statistical significance compared with
vehicle controls. ROS production by DCF was relatively modest by comparison, resulting in a statistically significant 1- to 2-fold increase at 3 hours for the 1 mM dose (Fig. 4B). DCF ROS induction appeared to indicate a dose response at 3 hours. DCF-AG demonstrated a clearer time-dependent ROS production culminating with a 5.5-fold increase at 3 hours for the 1 mM dose (Fig. 4C). The 500 \( \mu \text{M} \) DCF-AG showed trends of increased ROS generation, though only for the 3-hour incubation, which yielded a 1.8-fold increase versus vehicle that was statistically significant.

**SOD Inhibition Assay.** The SOD inhibition assay was used to explore whether DCF or DCF-AG could inhibit SOD enzymatic activity. SOD incubations were noncell-based and consisted of a mixture of substrate, enzymes, inhibitor, and detection reagent. Rather than inhibiting SOD activity over the concentration range, DCF caused an apparent stimulation, with the stimulus becoming statistically significant at the 250 \( \mu \text{M} \) dose and beyond (Fig. 5). DCF-AG had an opposite effect and was associated with a dose-dependent decrease in SOD activity such that there was a striking 100% inhibition of SOD at the 1 mM dose (Fig. 5). Furthermore, a statistically significant inhibition of 27% was observed at the 250 \( \mu \text{M} \) DCF-AG dose.

**COX Inhibition Assay.** The pharmacology of DCF for COX enzymes has been thoroughly evaluated, yet the pharmacology for DCF-AG has not been characterized. Hence, the final aspect of our work was to explore DCF-AG inhibition of COX enzymes. COX inhibition assays were noncell-based and used isolated COX enzymes that were mixed with substrate, cofactor, and inhibitor. Selective inhibitors of COX-1 and COX-2 were used as controls. Inhibition was assessed by measuring the decreased synthesis of PGE\(_2\) from AA. A summary of the findings is listed in Table 2. SC-560 and DuP-691, as selective COX-1 and COX-2 inhibitors, had IC\(_{50}\) values of 0.00166 ± 0.00022 \( \mu \text{M} \) and 0.00714 ± 0.0007 \( \mu \text{M} \), respectively (Fig. 6A and Fig. 7A). DCF, as a nonselective COX inhibitor had COX-1 and COX-2 IC\(_{50}\) concentrations of 0.0206 ± 0.0037 \( \mu \text{M} \) and 0.103 ± 0.005 \( \mu \text{M} \), respectively (Fig. 6B and Fig. 7B). OH-DCF was more potent against COX-1 than COX-2 and reached an apparent plateau for COX-2 inhibition. The OH-DCF IC\(_{50}\) values were estimated to be 0.375 ± 0.075 \( \mu \text{M} \) and 21.2 ± 0.3 \( \mu \text{M} \) for COX-1 and COX-2, respectively (Fig. 6C and Fig. 7C). Last, DCF-AG was demonstrated to inhibit PGE\(_2\) synthesis, with COX-1 and COX-2 IC\(_{50}\) estimates of 0.620 ± 0.105 \( \mu \text{M} \) and 2.91 ± 0.36 \( \mu \text{M} \), respectively (Fig. 6D and Fig. 7D). COX-1 inhibition potency of DCF-AG was weaker compared with OH-DCF; however, COX-2 inhibition potency by DCF-AG was more intermediate with respect to DCF and OH-DCF.

**Discussion**

Our interest in exploring the toxicity attributed to DCF-AG was born through our initial work of characterizing the role
that efflux transporters have in modulating toxicity following acute DCF administration. We observed that mice lacking the efflux transporter Mrp3 were more susceptible to intestinal injury compared with WT (Scialis et al., 2015). Though the intestinal toxicity differences between WT and KO were unequivocal, the mechanisms behind those differences were uncertain. Immunohistochemical staining of adducts within the intestinal villi led us to theorize that DCF-AG, as a causative agent to the covalent adducts, was subjected to an active transport process.

The intestines are host to an array of transporters some of which may be operative with respect to DCF-AG transport (Drozdzik et al., 2014). One of the probable candidates for DCF-AG uptake would be OATP2B1, which is known to mediate uptake of glucuronide conjugates (Gao et al., 2012; Grosser et al., 2014). Thus, OATP2B1 was investigated for DCF-AG affinity using a stably transfected cell system. The HEK-OATP2B1 cells were not used as an intestinal model, but served as an in vitro tool to test the uptake of DCF-AG by OATP without concomitant transport by multidrug resistance–associated protein 3 (MRP3) expression of which in HEK cells is quite low compared with other transporters (Ahlin et al., 2009). Using a compartmental model (Poirier et al., 2008), we defined the kinetic parameters describing DCF-AG uptake by OATP2B1. Preliminary studies showed that OATPs increased intracellular DCF-AG concentrations to levels exceeding the initial buffer conditions (data not shown). On the basis of those observations, we investigated the activity of OATP2B1 as a concentrative force for DCF-AG uptake.

We report that OATP2B1 acts an uptake transporter for DCF-AG, and that its affinity for DCF-AG varies with extracellular pH. OATP2B1 transporter clearance for DCF-AG was 1.82 μl/min per milligram at pH 6.0, whereas the transport clearance at pH 7.4 was 1.23 μl/min per milligram (Table 1). These findings suggest OATP2B1 activity is greater at pH 6.0, which is a typical pH in the intestines (Evans et al., 1988). Modeling estimates of DCF-AG passive diffusion indicated passive clearance was nearly 2.1-fold greater at pH 6.0 compared with pH 7.4 (0.0522 versus 0.0242 μl/min per milligram, respectively). Despite the increased passive diffusion at pH 6.0, active uptake of DCF-AG would be dominant. DCF, in contrast, as a smaller molecule with high passive uptake, has no such limitations and can more freely enter cells
Overall, the OATP2B1 studies provide insight into how intestinal uptake of DCF-AG can occur. Our next studies indicated that DCF-AG is indeed cytotoxic, more so than DCF, and that cytotoxicity can manifest within 3 hours of exposure (Fig. 3B). The cytotoxic DCF-AG concentrations are physiologically relevant as they reflect the biliary concentrations detected in mice after an administration of 75 mg/kg of DCF (Scialis et al., 2015). Importantly, the upper concentration of 1 mM in the cytotoxicity assay reflects the lowest DCF-AG biliary concentration observed in our previous toxicokinetic mouse study. Furthermore, the cytotoxicity caused by DCF-AG was greater in HEK-OATP2B1 cells than observed for HEK wild-type in our preliminary assays (Supplemental Fig. 1). Cell death by DCF reached a maximum of 29% by 12 hours at 1 mM compared with nearly 62% cell death for DCF-AG by 3 hours. These data substantiate the findings reported in transport-deficient (TR–) rats, in which DCF-AG administration elicited greater intestinal injury compared with an equimolar dose of DCF (Seitz and Boelsterli, 1998).

OATP2B1 has a mouse homolog, Oatp2b1, which is expressed in the intestinal tract (Cheng et al., 2005). It is conceivable that Oatp-mediated uptake of DCF-AG, along with the cytotoxicity potential of DCF-AG, may have contributed to the increased enteropathy in Mrp3 KO mice since those mice had reduced capacity to eliminate DCF-AG compared with WT.

Oxidative stress, through generation of reactive oxygen species, may overwhelm a cell’s ability to maintain homeostatic redox levels. The pesticide rotenone is a known inducer of ROS, and exposure to rotenone results in cell death (Tamilselvam et al., 2013). We conducted ROS assays with DCF and DCF-AG to determine their ROS activity. DCF ROS induction was relatively weak, yet ROS production was significantly increased after 2 hours of exposure. The modest ROS increase by DCF in our assay was less than a nearly 6-fold increase in ROS caused by DCF after a 30-hour exposure in a hepatocyte model of cytotoxicity (Lim et al., 2006). DCF-AG instigated a dose-dependent increase in ROS with a maximal 5.5-fold increase after 3 hours. Given that ROS generation occurred from 1 to 3 hours with cytotoxicity detected from 3 to 12 hours, it is plausible that DCF-AG ROS production contributed to cell death in our assays. Possible pathways of ROS-induced cell death are inhibition of ATPases, oxidation of DNA, perturbation of the mitochondrial permeability transition pore, or protein inactivation (Cantoni et al., 1989; Martinez-Reyes and Cuezva, 2014).

Oxidative stress can occur through inhibition of superoxide dismutase, an important part of the cell’s antioxidant response system (Fukui and Zhu, 2010). Therefore, we conducted noncell-based SOD inhibition assays. DCF failed to yield any inhibition and surprisingly appeared to stimulate SOD activity (Fig. 5). A striking observation was the clear dose-dependent inhibition of SOD by DCF-AG, with 1 mM DCF-AG reducing SOD activity to nondetectable levels (Fig. 5). Prior evidence for SOD inhibition by a glucuronide was shown in Table 2.

<table>
<thead>
<tr>
<th>Compound</th>
<th>COX-1 IC$_{50}$ μM</th>
<th>COX-2 IC$_{50}$ μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC-560 (COX-1 selective)</td>
<td>0.00166 ± 0.00022</td>
<td>N.D.</td>
</tr>
<tr>
<td>DuP-697 (COX-2 selective)</td>
<td>N.D.</td>
<td>0.00714 ± 0.0007</td>
</tr>
<tr>
<td>DCF</td>
<td>0.0206 ± 0.0037</td>
<td>0.103 ± 0.005</td>
</tr>
<tr>
<td>OH-DCF</td>
<td>0.375 ± 0.075</td>
<td>21.2 ± 0.3</td>
</tr>
<tr>
<td>DCF-AG</td>
<td>0.620 ± 0.105</td>
<td>2.91 ± 0.36</td>
</tr>
</tbody>
</table>

N.D., not determined.
reported by Chiou and colleagues (1999). In their study, 5 mM suprofen acyl glucuronide reduced SOD activity by 88% after a 14-day treatment using a noncell-based in vitro model, whereas 5 mM suprofen decreased SOD activity by only 5%. Our data show that DCF-AG can elicit complete inhibition at lower doses and within a shorter time scale. Taken in context,
the SOD inhibition and ROS generation by DCF-AG may lead to sustained oxidative stress and cell death. DCF was developed as a treatment of inflammation and pain via inhibition of COX enzymes. Hydroxylated metabolites of DCF have been tested for COX inhibition, but there has been no investigation of DCF-AG's pharmacology. Hence, we sought to identify if DCF-AG possessed COX inhibitory activity. Our inhibition assays with COX-1 and COX-2 led to the novel finding that DCF-AG had apparent COX-1 and COX-2 IC\textsubscript{50} values of 0.620 ± 0.105 μM and 2.91 ± 0.36 μM, respectively (Table 2). The COX inhibition potency of DCF-AG was notably weaker compared with DCF, for which we determined IC\textsubscript{50} values of 0.0206 ± 0.0037 μM and 0.103 ± 0.005 μM for COX-1 and COX-2, respectively, values that are in line with published findings (Johnson et al., 1995).

The COX inhibition assays monitored formation of PGE\textsubscript{2}, which has several important physiologic functions such as protection of the GI mucosa, and PGE\textsubscript{2}-signaling deficiencies were associated with increased GI injury (Takeuchi, 2014). Mere inhibition of COX-1 or COX-2 is not sufficient to cause gastrointestinal injury. Administration to rats of a selective COX-1 or COX-2 inhibitor did not induce GI injury; however, coadministration of selective inhibitors caused extensive damage, implying that inhibition of both COX isoforms is essential to injury formation (Tanaka et al., 2001). Studies with COX-1 or COX-2 KO mice demonstrated that COX-1 activity promotes intestinal intactness, and COX-2 activity is necessary for healing of ulcers (Schmassmann et al., 2006).

That DCF-AG can inhibit both COX enzymes represents a novel finding and offers a possible cause for the enteropathy associated with DCF-AG exposure. In Fig. 8 we propose a toxicity model that captures our observations. The model is predicated on the transfer of DCF into the liver, whereupon it undergoes metabolism. Hepatic DCF-AG can be excreted into the blood via MRP3 or transported into the bile by breast cancer resistance protein (BCRP) or MRP2. Residual hepatic DCF-AG may adduct albumin or be sequestered by glutathione (Grillo et al., 2003). Biliary DCF-AG enters the small intestine at the proximal duodenal region, after which it may undergo conversion back to DCF by bacterial β-glucuronidase present in the gut microflora (Louis et al., 2014). Free DCF-AG may covalently adduct to the brush border or undergo active uptake by OATP2B1. Intracellular DCF-AG can induce cytotoxicity through ROS generation or SOD inhibition causing oxidative stress. The acidic environment of the intestinal lumen stabilizes DCF-AG by decreasing the rate of non-enzymatic hydrolysis. DCF-AG may be cleared from enterocytes if MRP3 is present and functional, whereas lack of MRP3 may result in greater DCF-AG retention and injury. COX inhibition by DCF-AG may potentiate enteropathy via loss of PGE\textsubscript{2} protection as well as interference of COX-2-directed wound healing. Finally, DCF is expected to contribute to intestinal injury in conjunction to DCF-AG via COX inhibition, oxidative stress, and ROS generation.

It may not be clear which of the proposed mechanisms are dominant or minor. Nonetheless, our results lay the foundation of a novel multifactorial process of intestinal injury attributable directly to DCF-AG. The in vitro assays detailed in the current work offer potential explanations and insight that have not been previously explored. In conclusion, we believe we have made a rational argument for the potential for DCF-AG to directly mediate toxicity and have provided mechanistic leads that could explain this toxicity.

Acknowledgments

The authors thank Drs. Chester Costales and A. David Rodrigues for the use of transfected HEK cells.

Authorship Contributions

Participated in research design: Manautou, Scialis. Conducted experiments: Scialis. Performed data analysis: Scialis. Wrote or contributed to the writing of the manuscript: Manautou, Scialis.

References


Address correspondence to: Dr. José E. Manautou, Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road, Storrs, CT 06269-3092. E-mail: jose.manautou@uconn.edu